lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed and are posted here as part of a 12-month trial. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com

A Pilot Study of a New Approach to Manage Dysregulated Inflammation Using Continuous Venous Hyperfiltration

35 Pages Posted: 28 Jan 2019

See all articles by Rafael García-Hernández

Rafael García-Hernández

Hospital Universitario Puerta del Mar

Reyes Gámiz-Sánchez

Hospital Universitario Puerta del Mar

María V García-Palacios

Hospital Universitario Puerta del Mar

María I Espigares-López

Hospital Universitario Puerta del Mar

Francisco Miralles Aguiar

Hospital Universitario Puerta del Mar

Enrique Calderón Seoane

Hospital Universitario Puerta del Mar

Antonio Pernia Romero

Hospital Universitario Puerta del Mar

Luis M Torres Morera

Hospital Universitario Puerta del Mar

Convehy Research Group

More...

Abstract

Background: Hemofiltration paradigms to manage critical patients who develop a dysregulated inflammatory response (DIR) are based on evaluating kidney function as an indicator of onset, adaptation and completion. Here we present the CONVEHY protocol, a Continuous Venous Hyperfiltration approach using high doses of citrate (as an anticoagulant and substitution liquid) and a non-specific adsorption membrane (AN69-ST heparin grafted). CONVEHY uses available tools to achieve clear kidney related and non-related objectives, and it is guided by the monitoring of pathophysiological responses.  

Methods: In a restrospective before-after clinical pilot study, the benefits of the CONVEHY were assessed in a surgery critical care unit (CCUs) in patients with DIR. We compared the response to hemofiltration with AN69- ST heparin grafted membranes when heparin (He, n=5: earlier protocol) or citrate (Ci, n=6: CONVEHY protocol) was used, evaluating their SOFA (He 11 ± 2·35; Ci 11 ± 3·63: p=0·54) and APACHE II (He 28·60 ± 9·40; Ci 24 ± 8·46: p=0·93) scores.

Findings: Hospitalization (He 35·2 ± 16·3 nights; Ci 9 ± 2·53: p=0·004), hospitalisation after release from the CCUs (He 40·25 ± 21·82; Ci 13·2 ± 4·09: p=0·063), the number of patients hospitalised >20 days (He 80%; Ci 0%: p=0·048), the days requiring mechanical ventilation (He 16 ± 5·66; Ci 4 ± 1·72: p=0·004), and the predicted mortality (55·39 ± 26·13% versus real mortality in both groups of 9·1%: p=0·004).

Interpretation: Under the conditions used in this study, the CONVEHY improves the outcomes in patients who develop a serious DIR. These data highlight the value in performing further studies to confirm it.  

Funding Statement: The authors state: "This study did not received any funding." 

Declaration of Interests: - The authors have not received any financing from any of the following organizations: National Institutes of Health (NIH), Wellcome Trust, Howard Hughes Medical Institute (HHMI), and all other financial support, including departmental or institutional funding.

-The authors have received financing from Baxter SL. (Parque Empresarial San Fernando, Edificio Londres. Avenida De Castilla, 2. 28830 San Fernando de Henares, Madrid) for the translation of the manuscript by a professional translator.

-RAFAEL GARCÍA-HERNÁNDEZ has done a consulting work and conferences inhospitals financed by Baxter SL (Parque Empresarial San Fernando, Edificio Londres. Avenida De Castilla, 2. 28830 San Fernando de Henares, Madrid)

Ethics Approval Statement: The protocol for the collection of the data was approved by the hospital’s Ethical Review Board, and 11 patients were selected for inclusion onto the study, obtaining their informed consent or that of a family member for them to participate in this study.

Suggested Citation

García-Hernández, Rafael and Gámiz-Sánchez, Reyes and García-Palacios, María V and Espigares-López, María I and Miralles Aguiar, Francisco and Calderón Seoane, Enrique and Pernia Romero, Antonio and Torres Morera, Luis M and Group, Convehy Research, A Pilot Study of a New Approach to Manage Dysregulated Inflammation Using Continuous Venous Hyperfiltration (January 21, 2019). Available at SSRN: https://ssrn.com/abstract=3321490

Rafael García-Hernández (Contact Author)

Hospital Universitario Puerta del Mar ( email )

Avda. Ana de Viya 21
Cádiz, 11009
Spain

Reyes Gámiz-Sánchez

Hospital Universitario Puerta del Mar ( email )

Avda. Ana de Viya 21
Cádiz, 11009
Spain

María V García-Palacios

Hospital Universitario Puerta del Mar ( email )

Avda. Ana de Viya 21
Cádiz, 11009
Spain

María I Espigares-López

Hospital Universitario Puerta del Mar ( email )

Avda. Ana de Viya 21
Cádiz, 11009
Spain

Francisco Miralles Aguiar

Hospital Universitario Puerta del Mar ( email )

Avda. Ana de Viya 21
Cádiz, 11009
Spain

Enrique Calderón Seoane

Hospital Universitario Puerta del Mar ( email )

Avda. Ana de Viya 21
Cádiz, 11009
Spain

Antonio Pernia Romero

Hospital Universitario Puerta del Mar ( email )

Avda. Ana de Viya 21
Cádiz, 11009
Spain

Luis M Torres Morera

Hospital Universitario Puerta del Mar ( email )

Avda. Ana de Viya 21
Cádiz, 11009
Spain

No contact information is available for Convehy Research Group

Click here to go to TheLancet.com

Go to TheLancet.com

Paper statistics

Abstract Views
77
Downloads
12